Loading the knowledge graph…

Knowledge graph · Cancer

Micropapillary Carcinoma

histology

Identifier: CI-CAN-00001219
Entity page: /cancer/micropapillary-carcinoma ↗
Edges: 25

Neighbours: 15 drugs6 trials
Drawn: 21 of 21 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Micropapillary Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 19show all (up to 200)
→ investigated in trials for	Doxorubicinsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Micropapillary Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody

Micropapillary Carcinoma studied in …STUDIED_INderived6 of 6
→ studied in	NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped CURATED_BROADER · 6 trials mapped (3 active)	—	—	Invasive Bladder Micropapillary Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02812420early Phase 1 · active not recruiting Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery · condition mapped ALIAS · 6 trials mapped (3 active)	—	—	Invasive Bladder Micropapillary Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02101788Phase 2/Phase 3 · completed Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 6 trials mapped (3 active)	—	—	Micropapillary Serous Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03744793Phase 2 · active not recruiting Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer · condition mapped ALIAS · 6 trials mapped (3 active)	—	—	Invasive Bladder Micropapillary Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03912818Phase 2 · terminated Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer · condition mapped ALIAS · 6 trials mapped (3 active)	—	—	Invasive Bladder Micropapillary Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00551070Phase 2 · completed Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer · condition mapped ONTOLOGY_EXACT · 6 trials mapped (3 active)	—	—	Micropapillary Serous Carcinoma	1	Observed	clinicaltrials	graph →

Micropapillary Carcinoma studied in …STUDIED_INderived6 of 6

→ studied in

NCT03866382Phase 2 · recruiting

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped CURATED_BROADER · 6 trials mapped (3 active)

—

Invasive Bladder Micropapillary Urothelial Carcinoma

Observed

clinicaltrials

graph →

→ studied in

NCT02812420early Phase 1 · active not recruiting

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery · condition mapped ALIAS · 6 trials mapped (3 active)

—

Invasive Bladder Micropapillary Urothelial Carcinoma

Observed

clinicaltrials

graph →

→ studied in

NCT02101788Phase 2/Phase 3 · completed

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 6 trials mapped (3 active)

—

Micropapillary Serous Carcinoma

Observed

clinicaltrials

graph →

→ studied in

NCT03744793Phase 2 · active not recruiting

Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer · condition mapped ALIAS · 6 trials mapped (3 active)

—

Invasive Bladder Micropapillary Urothelial Carcinoma

Observed

clinicaltrials

graph →

→ studied in

NCT03912818Phase 2 · terminated

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer · condition mapped ALIAS · 6 trials mapped (3 active)

—

Invasive Bladder Micropapillary Urothelial Carcinoma

Observed

clinicaltrials

graph →

→ studied in

NCT00551070Phase 2 · completed

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer · condition mapped ONTOLOGY_EXACT · 6 trials mapped (3 active)

—

Micropapillary Serous Carcinoma

Observed

clinicaltrials

graph →

Radial view

Every edge, grouped by relationship

Strongest chains